Of HIFs and hERVs: Neoantigen generation in kidney cancer
Cancer Cell · 2025
DOI: 10.1016/j.ccell.2025.03.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2025. Verfasst von Nicholas J Salgia und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; Jacobs School of Medicine and Biomedical Sciences, University a…. Hauptthemen laut MEDLINE: Kidney Neoplasms, Carcinoma, Renal Cell, Antigens, Neoplasm, Basic Helix-Loop-Helix Proteins. Die Arbeit nennt 10 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
New evidence published in Cell provides insight into the interplay between hypoxia-inducible factor activity and downstream neoantigen production in clear cell renal cell carcinoma (ccRCC). Jiang et al. show that HIF2α regulates expression of immunogenic human endogenous retroelements, with implications for antitumor immunity and immunotherapy responsiveness in ccRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: spal@coh.org.
Förderung
- NCI NIH HHS
Zitieren
APA
Salgia, N. J., Dizman, N., & Pal, S. K. (2025). Of HIFs and hERVs: Neoantigen generation in kidney cancer. Cancer Cell. https://doi.org/10.1016/j.ccell.2025.03.001
Vancouver
Salgia NJ, Dizman N, Pal SK. Of HIFs and hERVs: Neoantigen generation in kidney cancer. Cancer Cell. 2025. doi:10.1016/j.ccell.2025.03.001
BibTeX
@article{Salgia2025,
author = {Salgia, Nicholas J and Dizman, Nazli and Pal, Sumanta K},
title = {Of HIFs and hERVs: Neoantigen generation in kidney cancer},
journal = {Cancer Cell},
year = {2025},
doi = {10.1016/j.ccell.2025.03.001}
}
EUVIMED